Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Aptose Announces Closing of Public Offering of Common Shares

Jun 03, 2019 8:38am EDT

Aptose to Present at the Jefferies 2019 Healthcare Conference

May 31, 2019 8:00am EDT

Aptose Announces Pricing of Public Offering of Common Shares

May 30, 2019 9:01am EDT

Aptose Announces Proposed Public Offering of Common Shares

May 29, 2019 4:22pm EDT

Aptose Biosciences Establishes New At-The-Market Facility

May 24, 2019 5:43pm EDT

Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association

May 16, 2019 10:02am EDT

Aptose to Present at May Investor Conferences

May 13, 2019 8:15am EDT

Aptose Announces Commencement of Previously Announced $20.0 Million Common Share Purchase Agreement with Aspire Capital Fund, LLC

May 10, 2019 7:24pm EDT

Aptose Reports Results for the First Quarter Ended March 31, 2019

May 07, 2019 4:01pm EDT

Aptose to Present at the Bloom Burton & Co. Healthcare Investor Conference 2019

Apr 24, 2019 7:30am EDT
RSS
  • Prev
    • 1...
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • 21
    • 22
    • ...32
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences